3.20
Precedente Chiudi:
$3.19
Aprire:
$3.14
Volume 24 ore:
2,487
Relative Volume:
0.14
Capitalizzazione di mercato:
$16.10M
Reddito:
-
Utile/perdita netta:
$-16.35M
Rapporto P/E:
-1.0492
EPS:
-3.05
Flusso di cassa netto:
$-11.88M
1 W Prestazione:
+6.31%
1M Prestazione:
-2.44%
6M Prestazione:
-42.34%
1 anno Prestazione:
-33.30%
Lipocine Inc Stock (LPCN) Company Profile
Nome
Lipocine Inc
Settore
Industria
Telefono
801 994 7383
Indirizzo
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Confronta LPCN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
LPCN
Lipocine Inc
|
3.2899 | 16.10M | 0 | -16.35M | -11.88M | -3.05 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.64 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
606.43 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
616.17 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
253.46 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
250.00 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2021-06-24 | Iniziato | Cantor Fitzgerald | Overweight |
2020-12-10 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
2018-01-12 | Reiterato | H.C. Wainwright | Buy |
2018-01-11 | Downgrade | Canaccord Genuity | Buy → Hold |
2017-12-08 | Ripresa | H.C. Wainwright | Buy |
2016-10-07 | Iniziato | H.C. Wainwright | Buy |
2015-07-22 | Iniziato | ROTH Capital | Buy |
2015-06-23 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Lipocine Inc Borsa (LPCN) Ultime notizie
Press Release Distribution & PR Platform - ACCESS Newswire
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 (PR Newswire) - Aktiellt
Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com - Defense World
Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com - Defense World
Lipocine Inc. Reports 2024 Financial Turnaround - TipRanks
Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression - Yahoo
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - MarketScreener
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Testosterone, TRAVERSE, And A Label Change 15 Years In The Making - News & Insights
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - Quantisnow
Lipocine Turns Profitable: How $11.2M in Licensing Deals Transformed 2024 Results - StockTitan
Lipocine to change FDA labeling for testosterone products -March 12, 2025 at 09:59 am EDT - Marketscreener.com
Lipocine Announces FDA Labeling Changes for Testosterone Products - Citizentribune
Lipocine announces FDA labeling changes for testosterone products - TipRanks
FDA Lifts Critical Cardiovascular Warning for Testosterone Treatments: Major Win for Lipocine - StockTitan
Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com - The AM Reporter
LPCN stock touches 52-week low at $2.92 amid market challenges By Investing.com - Investing.com South Africa
LPCN stock touches 52-week low at $2.92 amid market challenges - Investing.com UK
Lipocine Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Marketscreener.com
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com - Defense World
Lipocine Updates Corporate Presentation in Recent 8-K Filing - Defense World
Lipocine (NASDAQ:LPCN) Receives Updated Regulatory Guidance for LPCN 1154 - Defense World
Lipocine plans phase 3 study for postpartum depression drug - MSN
Lipocine Inc. Receives Updated Regulatory Guidance on LPCN 1154 -February 06, 2025 at 09:30 am EST - Marketscreener.com
Lipocine plans phase 3 study for postpartum depression drug By Investing.com - Investing.com South Africa
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - The Herald Journal
Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com - Defense World
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Lipocine Updates Corporate Presentation, Files 8-K with SEC - Defense World
(LPCN) On The My Stocks Page - Stock Traders Daily
Lipocine Inc Azioni (LPCN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):